CN104140418B - 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途 - Google Patents

2-(2,4,5-取代苯胺)嘧啶衍生物及其用途 Download PDF

Info

Publication number
CN104140418B
CN104140418B CN201410401604.7A CN201410401604A CN104140418B CN 104140418 B CN104140418 B CN 104140418B CN 201410401604 A CN201410401604 A CN 201410401604A CN 104140418 B CN104140418 B CN 104140418B
Authority
CN
China
Prior art keywords
methyl
base
amino
compound
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410401604.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104140418A (zh
Inventor
朱孝云
唐春雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang homologous health medicine Limited by Share Ltd
Original Assignee
GUANGZHOU BOJI MEDICAL BIOTECHNOLOGY CO Ltd
Changzhou Runnuo Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGZHOU BOJI MEDICAL BIOTECHNOLOGY CO Ltd, Changzhou Runnuo Biological Technology Co Ltd filed Critical GUANGZHOU BOJI MEDICAL BIOTECHNOLOGY CO Ltd
Priority to CN201410401604.7A priority Critical patent/CN104140418B/zh
Publication of CN104140418A publication Critical patent/CN104140418A/zh
Priority to EP15832588.6A priority patent/EP3181559B8/en
Priority to KR1020177007190A priority patent/KR101937704B1/ko
Priority to AU2015303641A priority patent/AU2015303641B2/en
Priority to US15/553,892 priority patent/US10414756B2/en
Priority to CA2958095A priority patent/CA2958095C/en
Priority to PCT/CN2015/085714 priority patent/WO2016023422A1/zh
Priority to JP2017527959A priority patent/JP6418622B2/ja
Application granted granted Critical
Publication of CN104140418B publication Critical patent/CN104140418B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201410401604.7A 2014-08-15 2014-08-15 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途 Active CN104140418B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201410401604.7A CN104140418B (zh) 2014-08-15 2014-08-15 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途
US15/553,892 US10414756B2 (en) 2014-08-15 2015-07-31 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
KR1020177007190A KR101937704B1 (ko) 2014-08-15 2015-07-31 2-(2,4,5-치환 아닐린)피리미딘 유도체, 이의 약물 조성물 및 이의 용도
AU2015303641A AU2015303641B2 (en) 2014-08-15 2015-07-31 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
EP15832588.6A EP3181559B8 (en) 2014-08-15 2015-07-31 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
CA2958095A CA2958095C (en) 2014-08-15 2015-07-31 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
PCT/CN2015/085714 WO2016023422A1 (zh) 2014-08-15 2015-07-31 2-(2,4,5-取代苯胺)嘧啶衍生物、其药物组合物及其用途
JP2017527959A JP6418622B2 (ja) 2014-08-15 2015-07-31 2−(2,4,5−置換アニリン)ピリミジン誘導体、その薬物組成物及びその用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410401604.7A CN104140418B (zh) 2014-08-15 2014-08-15 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途

Publications (2)

Publication Number Publication Date
CN104140418A CN104140418A (zh) 2014-11-12
CN104140418B true CN104140418B (zh) 2016-08-24

Family

ID=51849768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410401604.7A Active CN104140418B (zh) 2014-08-15 2014-08-15 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途

Country Status (8)

Country Link
US (1) US10414756B2 (cg-RX-API-DMAC10.html)
EP (1) EP3181559B8 (cg-RX-API-DMAC10.html)
JP (1) JP6418622B2 (cg-RX-API-DMAC10.html)
KR (1) KR101937704B1 (cg-RX-API-DMAC10.html)
CN (1) CN104140418B (cg-RX-API-DMAC10.html)
AU (1) AU2015303641B2 (cg-RX-API-DMAC10.html)
CA (1) CA2958095C (cg-RX-API-DMAC10.html)
WO (1) WO2016023422A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092926A1 (zh) 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104140418B (zh) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途
CN105237515B (zh) * 2014-10-10 2018-06-05 益方生物科技(上海)有限公司 氘代嘧啶类化合物、其制备方法、药物组合物和用途
EP3205650B1 (en) * 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
CN105001208A (zh) * 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 一种表皮生长因子受体egfr抑制剂及其制备方法与用途
CN105153122B (zh) * 2015-08-27 2018-07-20 上海圣考医药科技有限公司 [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
WO2017035753A1 (zh) * 2015-08-31 2017-03-09 无锡双良生物科技有限公司 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途
CN106478605A (zh) * 2015-09-02 2017-03-08 上海页岩科技有限公司 嘧啶类化合物、其制备方法和医药用途
KR102029135B1 (ko) * 2015-12-27 2019-10-07 뉴폼 파마슈티컬스, 아이엔씨. 암 및 관련 질병 및 상태 치료용 중수소화된 화합물, 그의 조성물 및 방법
CN108610331A (zh) * 2016-01-22 2018-10-02 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
CN107043369A (zh) * 2016-02-06 2017-08-15 焦玉奇 2‑(2,4,5‑取代苯胺)嘧啶衍生物
AU2016399168B2 (en) * 2016-03-22 2021-01-21 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
KR102245280B1 (ko) * 2016-09-19 2021-04-27 난징 추앙트어 파마슈티컬 테크놀로지 컴퍼니 리미티드 중수소화 3-(4,5-치환 아미노피리미딘) 페닐 유도체 및 그의 응용
CN108129342A (zh) * 2016-11-30 2018-06-08 浙江九洲药物科技有限公司 一种奥希替尼中间体及其制备方法
CN108047205B (zh) * 2016-12-14 2019-08-27 河南真实生物科技有限公司 2-(2,4,5-取代苯氨基)嘧啶衍生物、其制备方法及其在制备抗肿瘤药物中的应用
CN106957304B (zh) * 2017-04-25 2017-12-01 孔令廷 一种石墨烯负载FeCl3催化剂的制备方法及其在制备抗癌药物中间体的用途
CN107192773B (zh) * 2017-05-17 2019-09-27 张家港威胜生物医药有限公司 一种检测奥希替尼含量和有关物质的高效液相法
CN108929311B (zh) * 2017-05-22 2020-07-28 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
JP6971390B2 (ja) * 2017-05-24 2021-11-24 ティーワイケー メディシンズ インコーポレーテッドTyk Medicines Inc. 重水素化azd9291の結晶形、製造方法および使用
CN108467385A (zh) * 2017-06-27 2018-08-31 浙江同源康医药股份有限公司 一种氘代奥斯替尼衍生物及其应用
TWI702205B (zh) * 2017-10-06 2020-08-21 俄羅斯聯邦商拜奧卡德聯合股份公司 表皮生長因子受體抑制劑
CN107954918B (zh) * 2017-11-30 2022-01-25 郑州泰基鸿诺医药股份有限公司 一种n-氘代甲基吲哚类化合物的合成方法
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CN110272420A (zh) * 2018-03-16 2019-09-24 江苏正大丰海制药有限公司 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法
CN110950847B (zh) * 2018-09-27 2022-11-01 浙江同源康医药股份有限公司 氘代azd9291化合物的新晶型及其用途
CN110003183A (zh) * 2019-04-09 2019-07-12 河南真实生物科技有限公司 2-(2,4,5-取代苯氨基)嘧啶衍生物及其晶形b
CN111909135A (zh) * 2020-08-15 2020-11-10 天津大学 一种azd9291氘代物甲磺酸盐新盐型及其制备方法
PY21114408A (es) * 2020-12-30 2023-06-21 Biocad Joint Stock Co Inhibidores del receptor del factor de crecimiento epidérmico
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
CN113582976B (zh) * 2021-08-24 2023-03-17 郑州大学 氘代2-取代苯胺-4-吲哚基嘧啶类衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009288108B2 (en) * 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
CN101676266B (zh) * 2008-09-19 2011-10-26 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
CN104140418B (zh) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092926A1 (zh) 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Also Published As

Publication number Publication date
CA2958095C (en) 2023-09-26
KR20170036107A (ko) 2017-03-31
CN104140418A (zh) 2014-11-12
AU2015303641B2 (en) 2018-04-12
JP6418622B2 (ja) 2018-11-07
US10414756B2 (en) 2019-09-17
WO2016023422A1 (zh) 2016-02-18
EP3181559B1 (en) 2018-10-03
KR101937704B1 (ko) 2019-01-14
AU2015303641A1 (en) 2017-03-23
EP3181559A1 (en) 2017-06-21
US20180016258A1 (en) 2018-01-18
EP3181559A4 (en) 2017-06-21
JP2017523247A (ja) 2017-08-17
CA2958095A1 (en) 2016-02-18
EP3181559B8 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
CN104140418A (zh) 新的2-(2,4,5-取代苯胺)嘧啶衍生物及其用途
ES2805359T3 (es) Inhibidores de ERK y sus usos
KR100633270B1 (ko) 5-아자퀴녹살린계 화합물, 이의 합성 방법, 이를 사용한 세린/트레오닌 단백질키나제 작용의 조절 방법 및 이를 포함하는 약제학적 조성물
CN103848829B (zh) 杂芳基炔烃化合物及其应用
CN102838590B (zh) 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
CA2905993A1 (en) Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
HK1206725A1 (en) Alkynyl heteroaromatic ring compound and application thereof
CN107382973A (zh) 作为btk抑制剂的5‑氨基吡唑甲酰胺衍生物及其制备方法和药物组合物
CN105348271A (zh) 喹唑啉类衍生物药用用途及其制备方法
US10689361B2 (en) Quinoline derivative and use thereof
CN108047205A (zh) 2-(2,4,5-取代苯氨基)嘧啶衍生物、其制备方法及其在制备抗肿瘤药物中的应用
CN109476672A (zh) 新型杂环衍生物化合物及其用途
CN105399734A (zh) 新型egfr抑制剂及其制备方法
JP2019524680A (ja) 抗腫瘍効果を有するイミダゾオキサゾール誘導体、及びそれを含む薬学的組成物
CN106749193A (zh) 吲唑取代的表皮生长因子受体抑制剂及其应用
JP7101781B2 (ja) Akt阻害剤としての塩形態及びその結晶形態
TW202325281A (zh) 具有mat2a抑制活性的嘧啶-2(1h)-酮并二環類化合物及其用途
CN113956234B (zh) 一种n-苯基取代1h-吲唑-3-胺类化合物及其制备和抗肿瘤活性的应用
CN108530428A (zh) 取代的嘧啶衍生物及其制备方法和药物用途
CN109053593A (zh) 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN108530429A (zh) 2-(2,4,5-取代苯胺)嘧啶衍生物
CN107663207A (zh) 一种新型egfr激酶抑制剂的甲磺酸盐结晶及制备方法
WO2024022412A1 (zh) 一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用
CN106699789A (zh) 一种含腈基芳基硼酸的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN103012367A (zh) 一种喹啉衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160215

Address after: 213100 Jiangsu city of Changzhou province Hehai West New District No. 106

Applicant after: CHANGZHOU RUNNUO BIOLOGICAL TECHNOLOGY CO., LTD.

Address before: 201301 Shanghai city Pudong New Area Town Culture Village 2 Building No. 3 room 402

Applicant before: Zhu Xiaoyun

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160620

Address after: 213100 Jiangsu city of Changzhou province Hehai West New District No. 106

Applicant after: CHANGZHOU RUNNUO BIOLOGICAL TECHNOLOGY CO., LTD.

Applicant after: Guangzhou Boji Medical Biotechnology Co.,Ltd.

Address before: 213100 Jiangsu city of Changzhou province Hehai West New District No. 106

Applicant before: CHANGZHOU RUNNUO BIOLOGICAL TECHNOLOGY CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Double layer cyclic 4-belts filtered well

Effective date of registration: 20171108

Granted publication date: 20160824

Pledgee: TETRANOV PHARMACY STOCK INC.

Pledgor: CHANGZHOU RUNNUO BIOLOGICAL TECHNOLOGY CO., LTD.

Registration number: 2017990001040

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20171214

Granted publication date: 20160824

Pledgee: TETRANOV PHARMACY STOCK INC.

Pledgor: CHANGZHOU RUNNUO BIOLOGICAL TECHNOLOGY CO., LTD.

Registration number: 2017990001040

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180105

Address after: 313100 Zhejiang Huzhou city Changxin Economic Development Zone Mingzhu road 1278 Changxin World Trade Building A 14 floor 1403-2 room

Patentee after: Zhejiang homologous health medicine Limited by Share Ltd

Address before: 213100 Jiangsu city of Changzhou province Hehai West New District No. 106

Co-patentee before: Guangzhou Boji Medical Biotechnology Co.,Ltd.

Patentee before: CHANGZHOU RUNNUO BIOLOGICAL TECHNOLOGY CO., LTD.